文献速递湿疹皮炎与荨麻疹

JAK抑制剂治疗特应性皮炎的心血管与血栓栓塞风险:全球队列研究

Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis: A global cohort study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-07-21

本研究利用TriNetX全球数据库,经倾向性评分匹配比较特应性皮炎患者启动JAK抑制剂与度普利尤单抗、甲氨蝶呤或环孢素治疗后的心血管与血栓栓塞风险。结果显示,与度普利尤单抗相比,JAK抑制剂显著增加肺栓塞和深静脉血栓风险;与甲氨蝶呤相比,深静脉血栓风险亦增加;心肌梗死和卒中风险未见统计学升高。

要点

  • 与度普利尤单抗相比,JAK抑制剂增加肺栓塞和深静脉血栓风险。
  • 与甲氨蝶呤相比,JAK抑制剂增加深静脉血栓风险。
  • 心肌梗死和卒中风险在JAK抑制剂组未见统计学升高。

核心结论

  • 特应性皮炎患者使用JAK抑制剂与度普利尤单抗和甲氨蝶呤相比,肺栓塞和深静脉血栓风险轻度增加。
  • 研究结果强调处方JAK抑制剂时需仔细选择患者并评估血栓风险。

研究设计与样本

  • 利用TriNetX全球数据库开展倾向性评分匹配的队列研究。
  • 比较特应性皮炎患者启动JAK抑制剂与度普利尤单抗(n=1006)、甲氨蝶呤(n=958)或环孢素(n=948)治疗。
  • 评估3年内心肌梗死、卒中、肺栓塞和深静脉血栓的发生率。

主要发现

  • 与度普利尤单抗相比,JAK抑制剂组肺栓塞风险显著更高(HR 2.75;95%CI 1.19至6.38;p=0.014)。
  • 与度普利尤单抗相比,JAK抑制剂组深静脉血栓风险显著更高(HR 2.54;95%CI 1.14至5.64;p=0.017)。
  • 与度普利尤单抗相比,每1000例启动JAK抑制剂的患者分别额外增加8例肺栓塞和9例深静脉血栓。
  • 与甲氨蝶呤相比,JAK抑制剂组深静脉血栓风险增加(HR 2.41;95%CI 1.14至5.08;p=0.017),每1000例启动JAK抑制剂的患者额外增加7例深静脉血栓。
  • 与任一对照药相比,JAK抑制剂组心肌梗死和卒中风险均未统计学显著升高。

临床怎么用

  • 处方JAK抑制剂前应评估患者血栓栓塞风险,并谨慎选择患者。
  • 对高危血栓栓塞风险的特应性皮炎患者,可优先考虑度普利尤单抗等替代治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Janus kinase (JAK) inhibitors are increasingly used for moderate-to-severe atopic dermatitis (AD). However, concerns have emerged regarding their cardiovascular safety profile, particularly the risk of thromboembolic complications. Evidence specific to AD populations remains sparse. OBJECTIVES: To evaluate the real-world risk of myocardial infarction (MI), stroke, pulmonary embolism (PE) and deep vein thrombosis (DVT) among patients with AD treated with JAK inhibitors relative to those treated with dupilumab, methotrexate and cyclosporine. METHODS: Using the TriNetX global database, we conducted three propensity score-matched analyses comparing AD patients initiating JAK inhibitors with those receiving dupilumab (n = 1006), methotrexate (n = 958) or cyclosporine (n = 948). The incidence of MI, stroke, PE and DVT over 3 years was assessed. RESULTS: The risk of PE (hazard ratio [HR], 2.75; 95% confidence interval [CI], 1.19 to 6.38; p = 0.014) and DVT (HR, 2.54; 95% CI, 1.14 to 5.64; p = 0.017) was significantly higher among patients treated with JAK inhibitors relative to dupilumab, with a risk difference of eight and nine additional cases of PE and DVT/1000 patients starting JAK inhibitors, respectively. Relative to methotrexate, JAK inhibitors were associated with an increased risk of DVT (HR, 2.41; 95% CI, 1.14 to 5.08; p = 0.017), with a risk difference of seven additional cases/1000 patients starting JAK inhibitors. The risk of MI and stroke was not statistically elevated under JAK inhibitors in comparison to any of the comparators. CONCLUSIONS: JAK inhibitor use in patients with AD is associated with a slightly increased risk of PE and DVT compared to dupilumab and methotrexate. These findings underscore the need for careful patient selection and thrombotic risk assessment when prescribing JAK inhibitors.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Kridin K, Kridin S, Mayer E, et al. Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis: A global cohort study. J Eur Acad Dermatol Venereol. 2025. PMID: 40689675. doi:10.1111/jdv.20864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。